These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

520 related articles for article (PubMed ID: 27888710)

  • 1. PLK1, A Potential Target for Cancer Therapy.
    Liu Z; Sun Q; Wang X
    Transl Oncol; 2017 Feb; 10(1):22-32. PubMed ID: 27888710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PLK1 (polo like kinase 1) inhibits MTOR complex 1 and promotes autophagy.
    Ruf S; Heberle AM; Langelaar-Makkinje M; Gelino S; Wilkinson D; Gerbeth C; Schwarz JJ; Holzwarth B; Warscheid B; Meisinger C; van Vugt MA; Baumeister R; Hansen M; Thedieck K
    Autophagy; 2017 Mar; 13(3):486-505. PubMed ID: 28102733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting Polo-like kinase 1 in SMARCB1 deleted atypical teratoid rhabdoid tumor.
    Alimova I; Pierce AM; Harris P; Donson A; Birks DK; Prince E; Balakrishnan I; Foreman NK; Kool M; Hoffman L; Venkataraman S; Vibhakar R
    Oncotarget; 2017 Nov; 8(57):97290-97303. PubMed ID: 29228610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SUMOylation Promotes Nuclear Import and Stabilization of Polo-like Kinase 1 to Support Its Mitotic Function.
    Wen D; Wu J; Wang L; Fu Z
    Cell Rep; 2017 Nov; 21(8):2147-2159. PubMed ID: 29166606
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A selective inhibitor of the Polo-box domain of Polo-like kinase 1 identified by virtual screening.
    Abdelfatah S; Berg A; Böckers M; Efferth T
    J Adv Res; 2019 Mar; 16():145-156. PubMed ID: 30899597
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The toxicity of dysregulated Plk1 activity revealed by its suppressor mutations.
    Kamakura N; Takahashi M; Jo M
    Genes Cells; 2023 Jul; 28(7):503-515. PubMed ID: 37119463
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of a novel Polo-like kinase 1 inhibitor that specifically blocks the functions of Polo-Box domain.
    Chen Y; Zhang J; Li D; Jiang J; Wang Y; Si S
    Oncotarget; 2017 Jan; 8(1):1234-1246. PubMed ID: 27902479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Silencing of polo-like kinase (Plk) 1 via siRNA causes induction of apoptosis and impairment of mitosis machinery in human prostate cancer cells: implications for the treatment of prostate cancer.
    Reagan-Shaw S; Ahmad N
    FASEB J; 2005 Apr; 19(6):611-3. PubMed ID: 15661849
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Re-investigating PLK1 inhibitors as antimitotic agents.
    Delacour Q; Gavet O
    Mol Cell Oncol; 2017; 4(6):e1356430. PubMed ID: 29209646
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The small-molecule inhibitor BI 2536 reveals novel insights into mitotic roles of polo-like kinase 1.
    Lénárt P; Petronczki M; Steegmaier M; Di Fiore B; Lipp JJ; Hoffmann M; Rettig WJ; Kraut N; Peters JM
    Curr Biol; 2007 Feb; 17(4):304-15. PubMed ID: 17291761
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitory effect of Polo-like kinase 1 depletion on mitosis and apoptosis of gastric cancer cells.
    Chen XH; Lan B; Qu Y; Zhang XQ; Cai Q; Liu BY; Zhu ZG
    World J Gastroenterol; 2006 Jan; 12(1):29-35. PubMed ID: 16440413
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemical genetics reveals the requirement for Polo-like kinase 1 activity in positioning RhoA and triggering cytokinesis in human cells.
    Burkard ME; Randall CL; Larochelle S; Zhang C; Shokat KM; Fisher RP; Jallepalli PV
    Proc Natl Acad Sci U S A; 2007 Mar; 104(11):4383-8. PubMed ID: 17360533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A Synthetic Dosage Lethal Genetic Interaction Between CKS1B and PLK1 Is Conserved in Yeast and Human Cancer Cells.
    Reid RJ; Du X; Sunjevaric I; Rayannavar V; Dittmar J; Bryant E; Maurer M; Rothstein R
    Genetics; 2016 Oct; 204(2):807-819. PubMed ID: 27558135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterologous expression of mammalian Plk1 in Drosophila reveals divergence from Polo during late mitosis.
    Pearson J; Godinho SA; Tavares A; Glover DM
    Exp Cell Res; 2006 Apr; 312(6):770-81. PubMed ID: 16412419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MCC1019, a selective inhibitor of the Polo-box domain of Polo-like kinase 1 as novel, potent anticancer candidate.
    Abdelfatah S; Berg A; Huang Q; Yang LJ; Hamdoun S; Klinger A; Greten HJ; Fleischer E; Berg T; Wong VKW; Efferth T
    Acta Pharm Sin B; 2019 Sep; 9(5):1021-1034. PubMed ID: 31649851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Emerging Role of Polo-Like Kinase 1 in Epithelial-Mesenchymal Transition and Tumor Metastasis.
    Fu Z; Wen D
    Cancers (Basel); 2017 Sep; 9(10):. PubMed ID: 28953239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thoughts on the current assessment of Polo-like kinase inhibitor drug discovery.
    Strebhardt K; Becker S; Matthess Y
    Expert Opin Drug Discov; 2015 Jan; 10(1):1-8. PubMed ID: 25263688
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the regulation and function of human polo-like kinase 1 (PLK1): effects of overexpression on cell cycle progression.
    Mundt KE; Golsteyn RM; Lane HA; Nigg EA
    Biochem Biophys Res Commun; 1997 Oct; 239(2):377-85. PubMed ID: 9344838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Silencing of polo-like kinase (Plk) 1 via siRNA causes inhibition of growth and induction of apoptosis in human esophageal cancer cells.
    Bu Y; Yang Z; Li Q; Song F
    Oncology; 2008; 74(3-4):198-206. PubMed ID: 18714168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Mitotic Cancer Target Polo-Like Kinase 1: Oncogene or Tumor Suppressor?
    de Cárcer G
    Genes (Basel); 2019 Mar; 10(3):. PubMed ID: 30862113
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.